Cost-effectiveness analysis of metformin and glimepiride therapy in patients with type 2 diabetes mellitus at cilongok i health center
Keywords:
Cost Effectiveness Analysis, Type 2 DM, Glimepiride, MetforminAbstract
Diabetes mellitus (DM) is a disease caused by disorders in the pancreatic organs that cause a decrease in the amount of insulin resulting in an increase in blood sugar. DM is the sixth leading cause of death in the world and the third in Indonesia. This metabolic disease is a disease that requires a lot of time and money in treatment. The treatment of diabetes mellitus needs to be taken into account because it costs a lot of money and causes a loss of productive time, so a Cost Effectiveness Analysis (CEA) is required. The study was conducted to determine the cost-effectiveness of the most effective single therapy of metformin and glimepiride in terms of benefits and costs in type 2 DM patients at the Cilongok I Health Center. The analysis was carried out by comparing the total cost incurred with the effectiveness of the therapeutic results obtained. The analysis of the cost effectiveness of therapy uses the Average Cost Effectiveness (ACER) calculation method in outpatient installations at the Cilongok I Health Center for the period of January 2024 – June 2024. Results: DMT2 patients who used metformin and glimepyride monotherapy, the statistical results showed that the most drug use was metformin and the analysis of metformin effectiveness had a lower ACER value of Rp. 798,136 with an effectiveness of 83.72% while glimepiride was Rp. 1,093,565 with an effectiveness of 72.72%. Conclusion: Based on the calculation of the ACER analysis method, the administration of metformin therapy alone is more cost-effective than glimepiride alone, the use of metformin as the main choice in the management of DMT2 can optimize health expenditure, improve the accessibility of care for patients and a sustainable and cost-effective treatment strategy
References
1. Lestari, Zulkarnain, Sijid SA. Diabetes Melitus: Review Etiologi, Patofisiologi, Gejala, Penyebab, Cara Pemeriksaan, Cara Pengobatan dan Cara Pencegahan. UIN Alauddin Makassar. 2021;(November):237–41.
2. Diane A, Al-Shukri NA, Bin Abdul Mu-u-min R, Al-Siddiqi HH. β-cell mitochondria in diabetes mellitus: a missing puzzle piece in the generation of hPSC-derived pancreatic β-cells? J Transl Med. 2022;20(1):1–10.
3. Kemenkes RI. Laporan Riskesdas 2018 Nasional.pdf. Jakarta: Kementerian Kesehatan Republik Indonesia; 2018.
4. IDF. Biaya Penanganan Diabetes di Indonesia Diproyeksikan Meningkat 33 % pada 2045. 2021;(Per):2045.
5. Fahmi NF, Firdaus N, Putri N. Pengaruh Waktu Penundaan Terhadap Kadar Glukosa Darah Sewaktu Dengan Metode Poct Pada Mahasiswa. Jurnal Nursing Update. 2020;11(2):1–11.
6. Sari DF, Kurniasih KI. Cost Minimalyzation Analysist Penggunaan Antidiabetik Metformin Dan Glimepirid Pada Pasien Diabetes Melitus Di Puskesmas Cimanggu 1. Seminar Nasional Penelitian dan Pengabdian Kepada Masyarakat (SNPPKM). 2023;265–71.
7. Lorensia A, De Queljoe D, Swari Santi MD. Cost-Effectiveness Analysis Kloramfenikol Dan Seftriakson Untuk Pengobatan Demam Tifoid Pada Pasien Dewasa Di Rumah Sakit Sanglah Denpasar. MPI (Media Pharmaceutica Indonesiana). 2019;2(2):105–12.
8. Rajasa DFY. Cost Effectiveness Analysis Penggunaan Metformin Dan Glimepirid Pada Terapi Diabetes Melitus Tipe 2 Pada Pasien Rawat Jalan Di Puskesmas Bantul 2 (Doctoral dissertation, Universitas Muhammadiyah Yogyakarta). 2023.
9. Meliawati NW, Lolo WA, Rundengan GE. Cost-Effectiveness Analysis of the Use of Metformin and Glimepiride in Patients With Type 2 Diabetes Mellitus Inpatient At the Hospital . Robert Wolter Mongisidi Manado City. Pharmacy Medical Journal. 2023;6(1):68–76.
10. Rakhmawati A. Korelasi Kadar Glukosa Darah Dengan Kolesterol Total Pada Pasien Diabetes Melitus Tipe 2 Di Puskesmas Purwokerto Selatan. Jurnal Bina Cipta Husada Vol. 2024;XX(2):32–41.
11. zhou. Age-related impairment of pancreatic beta-cell function: Pathophysiological and cellular mechanisms. Front Endocrinol (Lausanne). 2014;5(SEP):1–8.
12. Burkon LK, Nafisahh Nafisah, Prasetyo Tri Kuncoro, Dwi Arini. Efektivitas Buku Saku Sebagai Media Edukasi Dalam Meningkatkan Pengetahuan Diet Dan Kepatuhan Diet Pasien Diabetes Mellitus Tipe 2 Di Kecamtan Sumbang Banyumas. Prosiding Seminar Nasional dan Call for Papers. 2023;13(1):204–12.
13. Lemieux CL, deGroh M, Gibbons L, Morrison H, Jiang Y. A Tool to Assess Risk of Type 2 Diabetes in Canadian Adults. Can J Diabetes. 2020;44(5):445–7.
14. Jannah et al. 2021. Analisis Efektivitas Biaya Penggunaan Antidiabetik Oral Pada Pasien Diabetes Mellitus Tipe 2 Rawat Jalan Peserta Bpjs Di Rsud Bumiayu 2020. Pharmacy Peradaban Journal. 2021;1(2):20–9.
15. Yao QM, Wang B, An XF, Zhang JA, Ding L. Testosterone level and risk of type 2 diabetes in men: A systematic review and meta-analysis. Endocr Connect. 2018;7(1):220–31.
16. Marzuk RH, Oetari RA, Hanifah IR. Analisis Efektivitas Biaya Terapi Metformin dan Glimepiride pada Pasien Diabetes Melitus Tipe 2 di RSUD dr. Darsono Pacitan Tahun 2019. Jurnal Ilmu Farmasi dan Farmasi Klinik. 2023;20(1):20.
17. Akalu Y, Belsti Y. Hypertension and its associated factors among type 2 diabetes mellitus patients at Debre Tabor general hospital, northwest Ethiopia. Diabetes, Metabolic Syndrome and Obesity. 2020;13:1621–31.
18. PERKENI. Pedoman Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Dewasa Di Indonesia. 2021;
19. Baker C, Retzik-Stahr C, Singh V, Plomondon R, Anderson V, Rasouli N. Should metformin remain the first-line therapy for treatment of type 2 diabetes? Ther Adv Endocrinol Metab. 2021;12:1–13.
20. Astari C. Pola Pengobatan Insulin dan Ace - Inhibitor pada Pasien Diabetes Melitus Tipe 2 dengan Hipertensi Terhadap Kontrol Glikemik dan Tekanan Darah. Sasambo Journal of Pharmacy. 2020;1(2):34–40.
21. Tonin FS, Aznar-Lou I, Pontinha VM, Pontarolo R, Fernandez-Llimos F. Principles of pharmacoeconomic analysis: The case of pharmacist-led interventions. Pharm Pract (Granada). 2021;19(1):1–10.
22. ADA. Standards of Care in Diabetes-2023 Abridged for Primary Care Providers American Diabetes Association. American Diabetes Association. 2023;41(1):1–28.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Delia Puspita, Fauziah, Galih Samodra (Author)
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
